Genome editing technology, such as CRISPR–Cas, has great potential in the study of rheumatic disease genetics, including in discovering disease-associated genes and regulatory regions, in validating causal variants and in characterizing important cell types and cell states.
- Yuriy Baglaenko
- Dana Macfarlane
- Soumya Raychaudhuri
